Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL

Fcpm Iii Services B.V. lifted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 6.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,158,368 shares of the company’s stock after acquiring an additional 248,672 shares during the quarter. Replimune Group makes up approximately 3.5% of Fcpm Iii Services B.V.’s holdings, making the stock its 7th biggest position. Fcpm Iii Services B.V. owned about 5.30% of Replimune Group worth $17,424,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Replimune Group in the second quarter worth $69,000. Russell Investments Group Ltd. increased its stake in shares of Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after purchasing an additional 7,569 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock valued at $90,000 after purchasing an additional 9,235 shares during the period. Finally, Letko Brosseau & Associates Inc. bought a new stake in shares of Replimune Group during the 2nd quarter valued at $100,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Piper Sandler raised their price target on Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Wedbush boosted their price objective on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Replimune Group Price Performance

REPL stock opened at $7.14 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The company’s fifty day moving average price is $7.73 and its 200-day moving average price is $7.68. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $13.24. The company has a market capitalization of $589.55 million, a PE ratio of -2.08 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, equities analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.